Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaihu Qinggan Tang (CHQGT) is a traditional Chinese medicine (TCM) herbal formula traditionally used to treat inflammatory and infectious conditions associated with the Liver and Gallbladder channels, specifically those classified under 'Liver Channel Heat Accumulation Syndrome.' The formula is currently being investigated as a therapeutic intervention for granulomatous mastitis (GM), a chronic, benign inflammatory disease of the breast that often mimics carcinoma. CHQGT is composed of multiple herbal ingredients, typically including *Bupleuri Radix* (Chaihu), *Scutellariae Radix* (Huangqin), and *Gardeniae Fructus* (Shanzhi), which collectively exert anti-inflammatory, immunomodulatory, and analgesic effects. In clinical research, it is often evaluated as an alternative or adjunct to corticosteroid therapy (such as methylprednisolone) to achieve disease remission and reduce recurrence rates while avoiding the systemic side effects associated with long-term steroid use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaihu Qinggan Tang.